{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-039032","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.179587+00:00","generated_at":"2026-06-15T02:27:19.103028+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adial Q1 net loss $2.9M; cash $2.3M; sells Purnovate for up to $83M milestones","bullets":["Q1 2023 net loss $2.9 million, flat YoY; cash $2.3M vs $4.0M at Dec 2022.","Sold Purnovate assets to Adovate for $0.45M upfront + up to $83M milestones + 19.9% equity stake.","Engaged The Keswick Group for partnering; awaiting regulatory meeting minutes from FDA, EMA agencies.","Closed ATM offering of 1.83M shares at $0.41 for gross $750K.","Cash runway expected into Q1 2024, helped by non-dilutive Purnovate sale proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-039032","json":"https://secwatch.observer/filing/0001213900-23-039032.json","markdown":"https://secwatch.observer/filing/0001213900-23-039032.md","text":"https://secwatch.observer/filing/0001213900-23-039032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023039032/0001213900-23-039032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023039032/ea178472-8k_adialpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:27:19.103028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51777db87fc5b01bbbca092d2a765ec58bb625a4","claim":"ADIAL PHARMACEUTICALS, INC. reported financial results for first quarter of 2023.","evidence_excerpt":"Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390023039032/0001213900-23-039032-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}